Research programme: immunoconjugates - MultiCell Immunotherapeutics/OXIS Biotech

Drug Profile

Research programme: immunoconjugates - MultiCell Immunotherapeutics/OXIS Biotech

Alternative Names: Antibody-drug conjugates - OXIS Biotech; OXS 1750

Latest Information Update: 15 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MultiCell Immunotherapeutics
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; SQSTM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Multiple myeloma; Osteolysis

Most Recent Events

  • 12 Mar 2015 Oxis Biotech licensed rights to OXS 2175 and OXS 4235 to MultiCell Immunotherapeutics to develop Immunocojugates comprising the drugs ,
  • 12 Mar 2015 Early research in Breast cancer, Multiple myeloma and Osteolysis associated with multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top